News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...
Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...
6don MSN
Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...
Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in the ...
Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...
The US Department of Health and Human Services is terminating a contract with drugmaker Moderna to develop a vaccine to ...
The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...
Bloomberg reported that the FDA recently granted Moderna Inc. (NASDAQ:MRNA) a narrower approval for its next-generation COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback